Trial record 3 of 56 for:    "Optic neuritis"

Neuroprotection With Phenytoin in Optic Neuritis

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by University College, London
Sponsor:
Collaborators:
National Multiple Sclerosis Society
Multiple Sclerosis Society of Great Britain and Northern Ireland
Information provided by (Responsible Party):
University College, London
ClinicalTrials.gov Identifier:
NCT01451593
First received: October 11, 2011
Last updated: December 20, 2013
Last verified: December 2013
  Purpose

Optic neuritis is caused by inflammation of the optic nerve and causes loss of vision in the affected eye. It is often associated with multiple sclerosis. Loss of vision after an attack of optic neuritis is caused by damage to the nerve fibres in the optic nerve. There are a number of factors that contribute to nerve fibre damage including increased levels of sodium within them, so blocking sodium entry could help to protect them against damage.

The purpose of this study is determine whether phenytoin (which blocks sodium entry into cells) can protect against loss of nerve fibres and prevent loss of vision after optic neuritis.


Condition Intervention Phase
Optic Neuritis
Multiple Sclerosis
Drug: Phenytoin
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis

Resource links provided by NLM:


Further study details as provided by University College, London:

Primary Outcome Measures:
  • Mean Retinal nerve fibre layer thickness [ Time Frame: Measured at entry and after 6 months ] [ Designated as safety issue: No ]
    The primary comparison will estimate active versus placebo mean retinal nerve fibre layer thickness of the retinal nerve fibre layer after 6 months, adjusted for the corresponding baseline measurement in the inaffected eye.


Secondary Outcome Measures:
  • Visual function [ Time Frame: Measured at entry and 6 months ] [ Designated as safety issue: No ]
    logMAR visual acuity, low contrast sensitvity using 1.25% and 2.5% sloan charts and colour vision using Farnsworth-Munsell 100 Hue test.

  • Visual evoked potentials [ Time Frame: Measured at entry (or within 4 weeks) and after 6 months ] [ Designated as safety issue: No ]
    Measurement of latency and amplitude will be performed. Axonal protection with phenytoin may enable axons to survive long enough to undergo remyelination. VEPS will give independant estimates of remyelination in the optic nerve.

  • Optic nerve and brain MRI [ Time Frame: Brain MRI will be performed at entry(or within 4 weeks) Optic nerve MRI will be performed at entry (or within 4 weeks) and after 6 months ] [ Designated as safety issue: No ]

    Brain MRI to detect demyelinating lesions that can be used in considering the prognosis for or diagnosis of multiple sclerosis using McDonald criteria.

    Optic nerve MRI - The following sequences will be performed:

    1. Fat sat T2 coronal-oblique to visualize the symptomatic lesion and obtain optic nerve area measurements.
    2. 3D gradient echo magnetization transfer sequence MTR to obtain measures of optic nerve myelination.
    3. Diffusion tensor imaging to obtain axial and radial diffusivity metrics of the optic nerve to determine axonal integrity.


Estimated Enrollment: 90
Study Start Date: November 2011
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: phenytoin
active arm of trial 1:1 allocation active versus placebo
Drug: Phenytoin
Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
Other Names:
  • Phenytoin sodium
  • Epanutin (Pfizer)
Placebo Comparator: placebo
1:1 allocation active versus placebo
Drug: Placebo
placebo identical in appearance to active IMP (phenytoin)

Detailed Description:

Demyelinating optic neuritis is the most common cause of acute reversible visual loss in young adults of Northern European Origin. There is a strong association with multiple sclerosis and up to 75% of British adults with acute clinically isolated optic neuritis go on to develop MS during long term follow up. Equally, 70% of MS patients have clinical evidence if optic nerve involvement during the course of their illness.

The pathology of the acute inflammatory lesion is comparable to the plaques found elsewhere in the CNS in MS. The retina and optic nerve therefore represent a discrete compartment of the CNS affected by the disease process that can be easily studied using a combination of clinical, electrophysiological and imaging techniques.

There is good evidence that axonal and neuronal degeneration are the primary pathological processes leading to irreversible disability in MS. Experimental models have demonstrated numerous mechanisms of axonal loss including adaptive changes in the demyelinated axonal membrane, in particular increased density of sodium channels leading to increased concentrations of intraaxonal sodium ions. Partial blockade of voltage gated sodium channels with drugs such as phenytoin has been shown to be neuroprotective in several experimental models of inflammatory axonal injury.

The retinal nerve fibre layer is unique in the CNS in that it is not myelinated and therefore is an ideal biomarker for the processes of neurodegeneration and neuroprotection.

Imaging of the retinal nerve fibre layer using optical coherence tomography and of the optic nerve using MRI both demonstrate that acute optic neuritis is associated with significant volume loss, and this correlates well with impaired visual function.

The primary aim of this trial is to assess whether sodium channel blockade with phenytoin has a neuroprotective effect on axonal loss after an attack of acute demyelinating optic neuritis. Secondary aims are to assess whether phenytoin improves visual outcome and remyelination and to assess the safety of the treatment.

90 patients with acute optic neuritis will be recruited into a double blind placebo controlled trial in which patients will be randomly allocated to receive either phenytoin or placebo for 3 months. Recruitment will take place at two trial sites in Sheffield and London. The trial is powered to detect a 50% beneficial effect on the primary outcome measure. Outcome will be measured at entry and after 6 months.Bias will be minimized by blinding assessing physicians and patients using active and placebo treatment of identical appearance.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of acute optic neuritis
  • Visual acuity in affected eye ≤ 6/12
  • Corrected vision in normal eye ≥ 6/6
  • No history of optic neuritis or other ocular disease in either eye
  • ≤ 14 days since onset of visual loss

Exclusion Criteria:

  • Contraindication or known allergy to Phenytoin
  • Contraindication to MRI
  • Use of a calcium channel or sodium channel blocker in the past 2 months
  • Corticosteroid use in the past 2 months
  • Tysabri infusion in the past 3 months
  • MS with major temperature dependent disability
  • Relapsing remitting MS of greater than 10 yrs duration or EDSS>3
  • Pregnancy
  • Breast Feeding
  • Significant cardiac, renal or liver abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01451593

Contacts
Contact: Rhian E Raftopoulos, MbChb r.raftopoulos@ucl.ac.uk

Locations
United Kingdom
National Hospital for Neurology and Neurosurgery Recruiting
London, United Kingdom, WC1 3BG
Contact: Rhian E Raftopoulos, MbChb       r.raftopoulos@ucl.ac.uk   
Royal Hallamshire Hospital Recruiting
Sheffield, United Kingdom
Contact: Simon Hickman         
Principal Investigator: Simon Hickman         
Sponsors and Collaborators
University College, London
National Multiple Sclerosis Society
Multiple Sclerosis Society of Great Britain and Northern Ireland
Investigators
Principal Investigator: Raju Kapoor, DM FRCP Institute of Neurology, University College London
  More Information

No publications provided by University College, London

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT01451593     History of Changes
Other Study ID Numbers: UCL/11/0083
Study First Received: October 11, 2011
Last Updated: December 20, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University College, London:
Optic neuritis
Multiple sclerosis
Retinal nerve fibre layer
Axonal loss
Neuroprotection
Phenytoin
MRI
Optical coherence tomography
Sodium Channel Blockers

Additional relevant MeSH terms:
Optic Neuritis
Multiple Sclerosis
Neuritis
Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Pathologic Processes
Phenytoin
Sodium Channel Blockers
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on July 26, 2014